Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer - read this article along with other careers information, tips and advice on BioSpace
Aristea Therapeutics has dosed the first patient in a phase 2b trial of its palmoplantar pustulosis candidate RIST4721, the company announced in a press release.A CXCR2 antagonist, RIST4721 is in development for the treatment of multiple inflammatory diseases, including the rare chronic skin condition palmoplantar pustulosis (PPP), which is characterized by recurrent sterile pustules on the palms